**IN THE CLAIMS**

Please amend the claims as follows:

1. (Amended) A compound of formula (I):




wherein $R_a$ and $R_b$ are independently C $_{1-8}$ alkyl, C $_{3-8}$ alkenyl, C $_{3-8}$ cycloalkyl,
(C $_{3-8}$ cycloalkyl) C $_{1-6}$ alkyl, or taken together with the nitrogen to which they are attached form a 4-7 membered heterocyclyl optionally including up to 3 additional heteroatoms;

n is 0-4;

one of $R_1$, $R_2$, and $R_3$ is G, and the remaining two are hydrogen or halo;

G is a nitrogen-containing group selected from one of the following:
$-OL_1Q$, $-L_2Q$, $-N(L_1Q)R_5$, $-L_3C(L_1Q)R_6R_7$, $-C(L_1Q)R_6R_7$,




(i)




(ii)




(iii)

wherein:

$L_1$ is C $_{2-6}$ alkylene, C $_{3-8}$ cycloalkylene, C $_{4-6}$ alkenylene, C $_{4-6}$ alkynylene, $C_{2-5}$ alkanoyl, (phenyl)C $_{1-6}$ alkylene, (naphthyl)C $_{1-6}$ alkylene, (C $_{2-5}$ heteroaryl)C $_{1-6}$ alkylene, (phenoxy)$C_{1-6}$ alkylene, or (C $_{2-5}$ heteroaryloxy)$C_{1-6}$ alkylene;

A' cont.

$L_2$ is $C_{1-6}$ alkylene, C $_{3-8}$ cycloalkylene, C $_{3-6}$ alkenylene, C $_{3-6}$ alkynylene, $C_{2-5}$ alkanoyl, (phenyl)C $_{1-6}$ alkylene, (naphthyl)C $_{1-6}$ alkylene, (C $_{1-5}$ heteroaryl)C $_{1-6}$ alkylene, (phenoxy)$C_{1-6}$ alkylene, (C $_{1-5}$ heteroaryloxy)$C_{1-6}$ alkylene, or (C $_{1-5}$ heteroarylthio)$C_{1-6}$ alkylene;

$L_3$ is $C_{1-6}$ alkylene, C $_{2-6}$ alkenylene, C $_{2-6}$ alkynylene, $C_{2-5}$ alkanoyl, (phenyl)C $_{1-6}$ alkylene, phenyl, naphthyl, (naphthyl)C $_{1-6}$ alkylene, C $_{1-5}$ heteroaryl)C $_{1-6}$ alkylene, (phenoxy)$C_{1-6}$ alkylene, (C $_{1-5}$ heteroaryloxy)$C_{1-6}$ alkylene, or C $_{2-5}$ heteroaryl;

$L_4$ is $C_{1-5}$ alkylene;

$L_5$ is $C_{1-5}$ alkylene;

$L_6$ is $C_{1-5}$ alkylene;

$L_7$ is $C_{1-5}$ alkylene or absent;

Q is $-NR_8R_9$ or a non-aromatic $C_{2-15}$ heterocyclyl ring system containing at least one nitrogen atom, Q being unsubstituted or substituted with between 1 and 3 additional heteroatoms selected from O, S, and N in each ring;

each of $R_5$ and $R_6$ is independently selected from hydrogen, $C_{1-8}$ alkyl, $C_{2-8}$ alkenyl, $C_{3-7}$ cycloalkyl, ($C_{3-7}$ cycloalkyl)$C_{1-6}$ alkylene, $C_{2-15}$ heterocyclyl, and ($C_{2-7}$ heterocyclyl)$C_{1-6}$ alkylene;

A1 cont.

$R_7$ is H, hydroxyl, halo, $C_{2-6}$ alkoxy or absent where the carbon linking $L_6$ and $L_7$ (or bonded to $R_6$) participates in a double bond;

each of $R_8$ and $R_9$ is independently selected from hydrogen, $C_{1-8}$ alkyl, $C_{3-8}$ alkenyl, $C_{3-7}$ cycloalkyl, ($C_{3-7}$ cycloalkyl)$C_{1-6}$ alkylene, $C_{2-15}$ heterocyclyl, phenyl, ($C_{2-15}$ heterocyclyl)$C_{1-6}$ alkylene, and (phenyl) $C_{1-6}$ alkylene;

$R_{10}$ is H, $C_{1-8}$ alkyl, $C_{3-8}$ alkenyl, $C_{3-7}$ cycloalkyl, ($C_{3-7}$ cycloalkyl)$C_{1-6}$ alkylene, ($C_{2-15}$ heterocyclyl)$C_{1-6}$ alkylene, or (phenyl) $C_{1-6}$ alkylene;

wherein each of the above alkyl, alkylene, alkenyl, alkenylene, alkynyl, alkynylene, heterocyclyl, cycloalkyl, and aryl groups may each be unsubstituted or substituted with between 1 and 3 substituents independently selected from halo, amino, nitro, hydroxyl, and $C_{1-3}$ alkyl;

wherein substituents of Q can be further selected from carboxamide, $C_{2-6}$ alkyl, $C_{1-8}$ heterocyclyl, N($C_{1-6}$ alkyl)($C_{1-8}$ heterocyclyl), NH($C_{1-8}$ heterocyclyl), ($C_{1-8}$ heterocyclyl) $C_{1-3}$ alkylene, O($C_{1-8}$ heterocyclyl), $C_{1-6}$ alkoxy, (phenyl)$C_{3-6}$ cycloalkyl-O-, phenyl, (phenyl) $C_{1-3}$ alkylene, N($C_{1-6}$ alkyl)[(phenyl)$C_{1-3}$ alkylene], and (phenyl)$C_{1-3}$ alkylene-O- where each of above heterocyclyl, phenyl, and alkyl groups may be unsubstituted or substituted with from 1 to 3 substituents independently selected from halogen, nitro, cyano, and $C_{1-3}$ alkyl;

or a pharmaceutically acceptable salt, ester, or amide thereof.

16. (Amended) A compound of claim 14, wherein Q is N-morpholinyl or N-piperidinyl, unsubstituted or substituted with between 1 and 3 substituents independently selected from hydroxyl, carboxamide, $C_{1-6}$ alkyl, $C_{1-8}$ heterocyclyl, N($C_{1-6}$ alkyl)($C_{1-8}$ heterocyclyl), NH($C_{1-8}$ heterocyclyl), ($C_{1-8}$ heterocyclyl)$C_{1-3}$ alkylene, $C_{1-8}$ heterocyclyl-O-, $C_{1-6}$ alkoxy, ($C_{3-6}$ cycloalkyl)-O-, phenyl, (phenyl)$C_{1-3}$ alkylene, N($C_{1-6}$ alkyl)[(phenyl)$C_{1-3}$ alkylene, and (phenyl)$C_{1-3}$ alkylene-O- where each of above heterocyclyl, phenyl, and alkyl groups may be unsubstituted or substituted with from 1 to 3 substituents independently selected from halogen, nitro, cyano, and $C_{1-3}$ alkyl.

17. (Amended) A compound of claim 16, wherein Q is substituted with a unsubstituted or substituted $C_{1-6}$ heterocyclyl group selected from: pyridyl, pyrimidyl, furyl, thiofuryl, imidazolyl, (imidazolyl)$C_{1-6}$ alkylene, oxazolyl, thiazolyl, 2,3-dihydro-indolyl, benzimidazolyl, 2-oxobenzimidazolyl, (tetrazolyl)$C_{1-6}$ alkylene, tetrazolyl, (triazolyl)$C_{1-6}$ alkylene, triazolyl, (pyrrolyl)$C_{1-6}$ alkylene, and pyrrolyl.

A2 cont.

21. (Amended) A compound of claim 20, wherein $R_8$ is H and $R_9$ is phenyl or aromatic $C_{1-8}$ heterocyclyl unsubstituted or substituted with 1-3 substituents independently selected from halo, nitro, cyano, and $C_{1-3}$ alkyl.

A3

53. (Amended) A compound of claim 1, 26, 27, or 41, isotopically-labelled to be detectable by positron emission tomography or single-photon emission computed tomography.

A4